

1-4
November
2026

Athens
Greece

19th International CMV Workshop & ECCI 2026



Megaron Athens International
Conference Centre

PROGRAMME

www.cmv-ecci2026.com

Scientific/Secretarial Support

 **free spirit**
Getting you there!

Table of contents

Welcome Message	Poster Presentations
03	20
Committees	Faculty Index
04	27
Programme at a glance	Workshop Information
05	32
Scientific Programme	Presentation Guidelines
Sunday 1 st November 2026	36
08	Certificates
Monday 2 nd November 2026	37
11	Poster Presentation Instructions
Tuesday 3 rd November 2026	38
14	General Information
Wednesday 4 th November 2026	39
18	Sponsors and Supporters
	42

1-4
november
Athens
Greece

19th International
CMV Workshop
& ECCI 2026
Megaron Athens International
Conference Centre



Welcome Message

Dear colleagues and friends,

On behalf of the Local Organizing Committee and the International Scientific Committee, it is our great pleasure to welcome you to the joint **19th International CMV Workshop and European Congenital Cytomegalovirus Initiative (ECCI) 2026**, which will take place from **1-4 November 2026** in the beautiful and historic city of **Athens, Greece**.

Together with CMV laboratory and clinical scientists, the ECCI Board, and the Scientific Committee, we are committed to delivering a high-quality, engaging, and dynamic scientific meeting. A Meeting that will provide an opportunity for the CMV research community to reconnect, foster new collaborations, and advance our shared mission.

Over the course of four full days, we will exchange knowledge and explore the latest data through vibrant scientific discussions. The program will feature *State-of-the-Art* keynote lectures from international experts covering a broad range of topics, including **treatment strategies, future vaccines, congenital CMV, CMV in transplantation**, and various aspects of **CMV immunology and virology**.

Participants will also have the opportunity to present their own research, engage with colleagues sharing similar interests, strengthen existing collaborations, and build new professional relationships. We warmly encourage you to submit your work, contribute your expertise, and join us in making this event a success.

Athens, with its rich cultural heritage, natural beauty, and modern infrastructure, offers the perfect setting for our conference. To that end, and in addition to the scientific program, we are organizing a warm and engaging social program to enhance your experience and encourage meaningful connections among attendees.

All in all, we aim at providing a holistic scientific and social networking experience, re-instating the **19th International CMV Workshop and ECCI 2026** where it really belongs: at the pinnacle of the CMV related events! Your active participation will not only be an invaluable contribution to that, but it will definitely be the deciding factor to its success. Thanking you in advance for your support, we look forward to welcoming you to Athens in November 2026!

Co-chairs of the CMV-ECCI 2026

Prof. George Sourvinos

Prof. Vana Papaevangelou



Committees

Local Co-Chairs

George Sourvinos

Vana Papaevangelou

Scientific Committee

Anna Alarcon	Camille Kotton	John Sinclair
Daniel Blázquez-Gamero	Tiziana Lazzarotto	Thomas Stamminger
Suresh Boppana	Marianne Leruez-Ville	Richard Stanton
Wolfram Brune	Hermione Lyall	Pamela Vallely
Caroline Deconick	Arnaud Marchant	Yves Ville
Ina Foulon	Michael McVoy	Ann Vossen
Karen Fowler	Edward Mocarski	Michael Weekes
Soren Gantt	Sallie Permar	Mark Wills
Laura Gibson	William Rawlinson	Dana Wolf
Chrissie Jones	Shannon Ross	Andrew Yurochko
Stipan Jonjić	Mark Schleiss	

Programme at a glance

1 November 2026	
08.45-09.00	WELCOME ADDRESSES
09.00-10.30	SESSION 1: CMV virology
10.30-11.00	COFFEE BREAK
11.00-12.30	SESSION 2: CMV and immune response (innate & acquired)
12.30-14.00	LUNCH BREAK AND POSTER VIEWING
13.00-14.00	CMV Workshop Organizers' Meeting
14.00-15.30	SESSION 3: Diagnosis and management of CMV infection in pregnancy
15.30-16.00	COFFEE BREAK
16.00-17.00	DEBATE 1: Antenatal screening versus universal newborn screening
17.00-17.30	OPENING LECTURE: The immune response to CMV
17.30-19.00	PARENTS ASSOCIATION SESSION
19.00	WELCOME RECEPTION

2 November 2026	
09.00-10.30	SESSION 4: Prognostic markers in fetal and neonatal cCMV infection
10.30-11.00	COFFEE BREAK
11.00-12.15	YOUNG INVESTIGATORS SESSION 1
12.15-13.45	SESSION 5: CMV and transplantation. The role of adoptive T cell therapy
13.45-14.30	LUNCH BREAK & POSTER PRESENTATION (I)
14.30-15.30	DEBATE 2: CMV and transplantation
15.30-16.00	COFFEE BREAK
16.00-16.30	LECTURE: The potential contribution of genome variation to outcomes in CMV disease
16.30-18.00	SESSION 6: Live panel discussion: Definition of asymptomatic cCMV infection
18.00-19.00	YOUNG INVESTIGATORS SESSION 2

Programme at a glance

3 November 2026	
09.00-10.30	SESSION 7: Challenges in management of children with cCMV
10.30-11.00	COFFEE BREAK
11.00-11.30	LATE BREAK ABSTRACTS
11.30-13.00	SESSION 8: Long term outcomes in children with cCMV
13.00-14.00	LUNCH BREAK & POSTER PRESENTATION (2)
14.00-15.30	SESSION 9: CMV and host interactions - latency
15.30-16.00	COFFEE BREAK
16.00-17.30	SESSION 10: CMV and immune correlates of protection
17.30-19.00	SESSION 11: Live panel discussion: Hot topic in transplant/immunocompromised patient

4 November 2026	
09.00-10.30	SESSION 12: Antiviral treatment for CMV and transplant patients
10.30-11.00	COFFEE BREAK
11.00-12.30	SESSION 13: CMV vaccines
12.30-14.00	LUNCH BREAK AND POSTER VIEWING
13.00-14.00	CMV Awareness and Prevention: Consideration of a Global Approach
14.00-15.45	SESSION 14: CMV prevention in transplantation
15.45-17.15	SESSION 15: CMV in preterm infants
17.15-17.30	CLOSING-HAND OVER
19.00	FAREWELL DINNER

19th International
CMV Workshop
& **ECCI 2026**
Megaron Athens International
Conference Centre

1-4
november
Athens
Greece

SCIENTIFIC PROGRAMME

1-4
november
Athens
Greece

19th International
CMV Workshop
& ECCI 2026
Megaron Athens International
Conference Centre

Scientific Programme
SUNDAY, 1 NOVEMBER 2026

08.45 - 09.00

Welcome Addresses

09.00 - 10.30

SESSION 1: CMV Virology

Chairs: **Edward Mocarski** (USA), **Wolfram Brune** (Germany)

09.00 - 09.50

Keynote Lectures

- Decoding cytomegalovirus using integrative multi-omics
Noam Stern-Ginossar (Israel)
- CMV's Dynamic Interactions with Host Metabolism
John Purdy (USA)

09.50 - 10.30

Oral Presentations (O001 - O004)

- O001.** Reconciling Functional and Evolutionary Descriptions of HCMV
Simon Rayner (Norway)
- O002.** Human Cytomegalovirus co-opts FcRn-mediated IgG transport to cross the placental barrier **Rebecca Göttler** (Germany)
- O003.** Novel insights into the HCMV "effectome" from multiomic analysis of single gene expressing cells **Theo von Wilmowski** (UK)
- O004.** Control of gamma delta T cells by human cytomegalovirus
Elizabeth Ferris (UK)

10.30 - 11.00

Coffee Break

11.00 - 12.30

SESSION 2: CMV and immune response (innate & acquired)

Chairs: **Arnaud Marchant** (Belgium), **Stipan Jonjić** (Croatia)

11.00 - 11.50

Keynote Lectures

- HCMV and Innate Cellular Immune Responses **Richard Stanton** (UK)
- What is CMV doing to your ovaries and adrenal glands?
Pathogenesis and immune responses **Vanda Juranić Lisnić** (Croatia)

11.50 - 12.30

Oral Presentations (O005 - O008)

O005. Soluble Immune Checkpoint Profiles in Congenital Cytomegalovirus (cCMV) Infection: A Balancing Act Between Activation, Exhaustion and Anergy? **Chrysanthi Eleni Loizou** (Greece)

O006. Transcriptional profiling of T cells and NK cells in infants with congenital CMV infection **Masako Shimamura** (USA)

O007. Evolution of HCMV non-primary infection and host immune response in HCMV-seropositive mothers of children attending day-care centers. An observational prospective study **Piera d'Angelo** (Italy)

O008. The role of IFN- α and IFN- β in the immune defence against viral infections **Verena Babl** (Austria)

12.30 - 14.00

Lunch Break & Poster viewing

FOYER

13.00 - 14.00

CMV Workshop Organizers' Meeting

Meeting on future meetings

MAIN
AUDITORIUM

14.00 - 15.30

SESSION 3: Diagnosis and management of CMV infection in pregnancy

Chairs: **Tiziana Lazzarotto** (Italy), **Pamela Vallely** (UK)

14.00 - 14.50

Keynote Lectures

- CMV in pregnancy: time is the essence **Marianne Leruez- Ville** (France)
- T cell Immunity to CMV during pregnancy and in the placenta **Clive Gray** (South Africa)

14.50 - 15.30

Oral Presentations (O009 - O012)

O009. Performance of serological and molecular markers to predict congenital CMV infection (cCMV) in offspring's of pre-immune pregnant women **Sonia Lacourt** (France)

O010. A Roadmap for Congenital Cytomegalovirus (CMV) Research in Australia and New Zealand: a Modified Delphi Consensus Informed by Lived Experience **Hayley Smithers Sheedy** (Australia)

1-4
november
Athens
Greece

19th International
CMV Workshop
& ECCI 2026
Megaron Athens International
Conference Centre

Scientific Programme
SUNDAY, 1 NOVEMBER 2026

O011. Pediatric follow up and outcomes of congenital Cytomegalovirus infection after maternal valaciclovir treatment. A multicenter Megal-Italy study **Elisabetta Venturini (Italy)**

O012. Observed changes in the cohort of cCMV-infected children post implementation of effective antiviral secondary prophylaxis in pregnant women with CMV infection **Vana Papaevangelou (Greece)**

15.30 - 16.00

Coffee Break

16.00 - 17.00

DEBATE 1: Antenatal screening versus universal newborn screening

Chair: **Caroline De Coninck (Belgium)**

Speakers: **Yves Ville (France)** and **Mark Schleiss (USA)**

17.00 - 17.30

**Opening Lecture
The immune response to CMV**

Chairs: **George Sourvinos (Greece)**, **Vana Papaevangelou (Greece)**

Invited Speaker: **Prof Mark Wills (UK)**

17.30 - 19.00

Parents Association Session

Chairs: **Chrissie Jones (UK)**, **Karen Fowler (USA)**

19.00

Welcome Reception

09.00 - 10.30

SESSION 4: Prognostic markers in fetal and neonatal cCMV infection

Chairs: **Suresh Boppa** (USA), **Hermione Lyall** (UK)

09.00 - 09.50

Keynote Lectures

- Prognostic cCMV biomarkers derived from ex vivo models and population-based studies **Dana Wolf** (Israel)
- Risk Stratification and Prognostic Markers in the Neonate **Daniel Blazquez Gamero** (Spain)

09.50 - 10.30

Oral Presentations (O013 - O015)

O013. Genomic diversity of congenital cytomegalovirus: first findings from the cCMV Sequencing Consortium **Cristina Venturini** (UK)

O014. Prognostic performance of a neonatal risk stratification model and the role of brain MRI in congenital Cytomegalovirus infection **Elisabetta Venturini** (Italy)

O015. Exploratory proteomics of amniotic fluid extracellular vesicles in congenital cytomegalovirus **Ishara Atukorala** (Australia)

10.30 - 11.00

Coffee Break

11.00 - 12.15

Young Investigators Session 1 (Y001-Y006 & LB001)

Chairs: **George Sourvinos** (Greece), **Christos Chatzakis** (Greece)

Y001. Human cytomegalovirus pentamer engages endothelin B receptor to trigger ERK/CK2-dependent histone lactylation which dictates viral permissiveness **Hatem Abouguendia** (Finland)

Y002. Cytomegalovirus infection in HIV-exposed preterm infants **Helen Payne** (UK)

Y003. Early Cytomegalovirus Screening and Treatment in Pregnancy: First Insights From a Swiss National Register **David Baud** (Switzerland)

1-4
november
Athens
Greece

19th International
CMV Workshop
& ECCI 2026
Megaron Athens International
Conference Centre

Scientific Programme
MONDAY, 2 NOVEMBER 2026

Y004. Neonatal Vδ1 γδ T Cells Balance Antiviral Immunity and Inflammatory Control During Acute CMV Infection **Tao Yang (Germany)**

Y005. Effect of Valaciclovir on Fetal Blood Parameters and Ultrasound in Congenital CMV infections: A Multicentre Case-Cohort Study
Léo Pomar (Switzerland)

Y006. Preliminary Safety and Efficacy of Valganciclovir With and Without Maternal Derived CMV Cytotoxic T-Lymphocytes (CTLs) as Adoptive Cellular Therapy in Neonates with Moderate/Severe Congenital CMV Infection (cCMV) (IND17449) (NCT055645989) **Mitchell Cairo (USA)**

LB(O)001. MAPKAP Kinase 2 Orchestrates Memory T Cell Inflation in Cytomegalovirus Infection **Eleni Panagiotti (USA)**

12.15 - 13.45

SESSION 5: CMV and transplantation; the role of Adoptive T cell therapy

Chairs: **John Sinclair (UK)**, **Andrew Yurochko (USA)**

12.15 - 13.05

Keynote Lectures

- Democratizing Cell Therapy: Allogeneic Virus-Specific T Cell Therapies for Transplant Recipients **Rajiv Khanna (Australia)**
- Off-the-Shelf Virus-Specific T Cells to Treat Viral Infections
Spyridoula Vasileiou (USA)

13.05 - 13.45

Oral Presentations (O016 - O018)

O016. Characterization and Immunologic Signatures of GMP Grade Related Donor Cytomegalovirus Virus (CMV) Cytotoxic T-Lymphocytes (CTLs) Manufactured by the CliniMACS Prodigy® CCS (IFN-gamma) System **Mitchell Cairo (USA)**

O017. The Safety and Efficacy of Related Donor Derived CMV Cytotoxic T-Lymphocytes Manufactured and Enriched by the CliniMACS Prodigy® CCS (IFN-gamma) System in Immunocompromised Children and Adolescents with Medically Refractory CMV Infections
Mitchell Cairo (USA)

O018. pp65-specific T cell response is a predictor of the risk for clinically significant HCMV infection after the stop of Letermovir prophylaxis
Daniele Lilleri (Italy)

13.45 - 14.30

Lunch Break & Poster Presentations Session 1 (page 21)

14.30 - 15.30

DEBATE 2: CMV and transplantation

Chair: **Ilkka Helanterä** (Finland)

Speakers: **Anders Åsberg** (Norway) and **Per Ljungman** (Sweden)

15.30 - 16.00

Coffee Break

16.00 - 16.30

LECTURE: The potential contribution of genome variation to outcomes in CMV disease

Chair: **Mark Schleiss** (USA)

Speaker: **Judith Breuer** (UK)

16.30 - 18.00

SESSION 6

Live panel discussion: Definition of asymptomatic cCMV infection

Daniel Blazquez Gamero, Gail J Demmler Harrison, Hermione Lyall, Vana Papaevangelou, William Rawlinson, Ann Vossen

18.00 - 19.00

Young Investigators Session 2 (Y007-Y012)

Chairs: **Karen Fowler** (USA), **Elizaveta Padalko** (Belgium)

Y007. The UK lags behind Southern Europe in the prevention, diagnosis and treatment of Congenital CMV **Annalie Shears** (UK)

Y008. Screening for congenital cytomegalovirus in infants born to mothers with HIV: An International Survey of Practice **Amelia Bennett** (UK)

Y009. The first viral 'deletome': systematic functional characterisation of every HCMV gene using CRISPR and multiomics **Yuchen Lin** (UK)

Y010. Persistently primed microglia restrict the reactivation of latent cytomegalovirus at the expense of neuronal synaptic connectivity **Andrea Mihalić** (Croatia)

Y011. JAK Independent Activation of STAT5 Promotes HCMV Reactivation in Primary Dendritic Cells **Aisha Fakhroo** (UK)

Y012. The assembly of the HCMV IE1 protein into distinct foci on mitotic chromosomes **Tejasv Gupta** (Poland)

09.00 - 10.30

SESSION 7: Challenges in management of children with cCMV

Chairs: **Shannon Ross** (USA), **Athanasios Michos** (Greece)

09.00 - 09.50

Keynote Lectures

- Antiviral treatment beyond neonatal period **Ann Vossen** (The Netherlands)
- Management of late-onset hearing loss **Ina Foulon** (Belgium)

09.50 - 10.30

Oral Presentations (O019 - O022)

O019. Neonatal characteristics and outcomes of asymptomatic congenital cytomegalovirus infection: A Single-Center Experience

Justyne Czech-Kowalska (Poland)

O020. Long-term neurodevelopmental impairment in children with clinically inapparent congenital CMV disease at birth: a prospective cohort study **Sofia Karagiannidou** (Greece)

O021. Quality of life among infants with congenital CMV and their caregivers **Andrew Handel** (USA)

O022. Plasma biomarkers are predictors of severity of brain abnormalities in infants with congenital cytomegalovirus **Helen Payne** (UK)

10.30 - 11.00

Coffee Break

11.00 - 11.30

Oral Presentations of Late Breaking Abstracts

Chairs: **Dirk Dittmer** (USA), **Eleni Nastouli** (UK)

LB(O)002. The RL11 family glycoprotein pUL11 Impairs NK Cell Antiviral Activity in HCMV Infection **Gantulga Ganbat** (Germany)

LB(O)003. Characteristics of cytomegalovirus shedding in household contacts of CMV-seropositive pregnant women: a longitudinal study in a high CMV seroprevalence population **Marisa Mussi-Pinhata** (Brazil)

LB(O)004. Antenatal CMV Evaluation of Screening (ACES) Study: Preliminary Results of a UK Pilot Implementation
Noa Mevorach Zussman (United Kingdom)

11.30 - 13.00

SESSION 8: Long term outcomes in children with cCMV

Chairs: **Ana Alarcon** (Spain), **Despoina Gkentzi** (Greece)

11.30 - 12.20

Keynote Lectures

- Importance of vestibular assessment and rehabilitation in congenital CMV infection **Natacha Teissier** (France)
- CMV and Autism **William Rawlinson** (Australia)

12.20 - 13.00

Oral Presentations (O023 - O026)

O023. Thrombocytopenia and subsequent hearing and neurodevelopment outcomes in children with congenital CMV **Despoina Gkentzi** (Greece)

O024. A neonatal prognostic score for infants with congenital cytomegalovirus infection (cCMVnet Score)
Daniel Blázquez-Gamero (Spain)

O025. Autism Spectrum Disorders in congenital cytomegalovirus infection **Serena Salomè** (Italy)

O026. Developing a Prediction Model for congenital Cytomegalovirus (cCMV)-associated Sensorineural Hearing Loss (SNHL)
Swetha Pinninti (USA)

13.00 - 14.00

Lunch Break & Poster Presentations Session 2 (page 24)

14.00 - 15.30

SESSION 9: CMV and host interactions – latency

Chairs: **Judith Breuer** (UK), **Thomas Stamminger** (Germany)

14.00 - 14.50

Keynote Lectures

- Current understanding of HCMV latency **Meaghan Hancock** (Canada)
- Targeting the latent reservoir **Emma Poole** (UK)

14.50 - 15.30

Oral Presentations (O027 - O030)

O027. Nucleosomal Sequestration of Human Cytomegalovirus Proteins IE1 and pp65 Limits Their Proteasomal Degradation and Promotes Establishment of Latency **Michael Nevels** (UK)

O028. Human cytomegalovirus antagonizes SMC5/6 driven genome silencing via UL35 instituted proteasomal degradation of SLF2
Thomas Stamminger (Germany)

O029. The Variable HCMV pUL9 shapes NK Cell Responses via Strain-Specific Activation of Killer Cell Immunoglobulin-like receptors

Nina Plückebaum (Germany)

O030. Neuroimmune regulation of neuron-restricted cytomegalovirus latency in the central nervous system **Fran Krstanović** (Croatia)

15.30 - 16.00

Coffee Break

16.00 - 17.30

SESSION 10: CMV and immune correlates of protection

Chairs: **Laura Gibson** (USA), **Daniele Lilleri** (Italy)

16.00 - 16.50

Keynote Lectures

- Immune correlates of protection from reactivation of CMV and BKV in kidney transplant recipients **Arnaud Marchant** (Belgium)
- Gamma delta T cells involvement against CMV infection after solid organ transplantation **Hannah Kaminski** (France)

16.50 - 17.30

Oral Presentations (O031 - O033 & LB005)

O031. Strategies for management of Human Cytomegalovirus (HCMV) reactivation in Hematopoietic stem cell transplant recipients (HSCTRs) during Letermovir prophylaxis **Daniele Lilleri** (Italy)

O032. Humoral and cellular immunity predict the risk of clinically significant CMV infection in kidney transplant recipients **Sylvain Verbanck** (Belgium)

O033. Increasing CMV Seroprevalence in Belgium: Results from a Nationwide Laboratory Survey **Emilie De Muynck** (Belgium)

LB(O)005. CMV-Scan, a high-resolution serological assay, distinguishes vaccine-induced responses from wild-type CMV infections among participants of the MSD V160 vaccine trial **Soren Gantt** (Canada)

17.30 - 19.00

SESSION 11: Live panel discussion: Hot topic in transplant/immunocompromised patient

Anders Asberg, Mario Fernandez-Ruiz, Ilkka Helanterä, Atul Humar, Genovefa Papanicolaou, Maria Stamouli

09.00 - 10.30

SESSION 12: Antiviral treatment for CMV and transplant patients

Chairs: **Manfred Marschall** (Germany), **Sotirios Tsiodras** (Greece)

09.00 - 09.50

Keynote Lectures

- Recent advances in antiviral treatment in solid organ transplant patients
Atul Humar (Canada)
- Optimizing CMV management in hematopoietic cell recipients
Genovefa Papanicolaou (USA)

09.50 - 10.30

Oral Presentations (O034 - O037)

- O034.** Letermovir resistance in French stem cell and solid organ graft recipients, from the Navire cohort and the National Reference Center database **Sophie Alain** (France)
- O035.** LAVR-289: A Safer New Weapon Against HCMV **Nader Bayda** (France)
- O036.** REACTR assay for rapid and user-friendly ganciclovir triphosphate monitoring in dried blood spots and peripheral blood mononuclear cells
Willow Chernoske (USA)
- O037.** Antigen-specific versus agnostic screening to develop broadly protective antibodies for immunotherapy against human cytomegalovirus
Hannah Lewis (USA)

10.30 - 11.00

Coffee Break

11.00 - 12.30

SESSION 13: CMV vaccines

Chairs: **Micheal McVoy** (USA), **Michael Weekes** (UK)

11.00 - 11.50

Keynote Lectures

- Novel gB epitopes as vaccine targets **Matthew Reeves** (UK)
- Targeting CMV entry **Jeremy Kamil** (USA)

11.50 - 12.30

Oral Presentations (O038 - O041)

O038. Cytomegalovirus Promotes Colon Cancer Metastasis: Prevention by an M83-Directed Vaccine **Yara Abdelkawy (Finland)**

O039. Domain V of glycoprotein B serves as key regulator of HCMV fusion **Madlen Mollik (Austria)**

O040. Controlling HCMV using engineered NK-mediated antibody dependent cellular cytotoxicity-inducing immunotherapies **Hannah Preston (UK)**

O041. Structural and immunological basis of cross-herpesvirus activity of a new humoral response induced by human cytomegalovirus vaccination **Anastasia Lankina (UK)**

12.30 - 14.00

Lunch Break & Poster viewing

FOYER

13.00 - 14.00

CMV Awareness and Prevention: Consideration of a Global Approach

Special Interest Luncheon Meeting

Vana Papaevangelou, Chrissie Jones, & Karen Fowler

In recent decades, awareness of CMV has increased gradually. Currently, effective global communication of health information remains challenging. Insufficient education and awareness regarding CMV complicate prevention discussions with women and families.

Join us to discuss CMV awareness and prevention messaging, and whether developing a global campaign tailored to our countries would interest stakeholders in the CMV community.

MAIN
AUDITORIUM

14.00 - 15.45

SESSION 14: CMV prevention in transplantation

Chairs: **Nikolaos Sipsas (Greece), Per Ljungman (Sweden)**

14.00 - 14.50

Keynote Lectures

- Management of CMV infection in solid organ transplant recipients **Mario Fernandez-Ruiz (Spain)**
- Current management of CMV in allogeneic stem cell transplant recipients **Per Ljungman (Sweden)**

14.50 - 15.45

Oral Presentations (O042 - O046)

- O042.** Structural mapping of novel gH/gL antibody epitopes reveals epitope-specific synergistic HCMV neutralization **Matthias Zehner (Germany)**
- O043.** Deciphering the Role of Checkpoint Pathways in Diminished Anti-HCMV T-Cell Functionality in the Elderly and Viraemic Solid Organ Transplant Patients **Sarah Jackson (UK)**
- O044.** A novel pp65-IGRA for monitoring cytomegalovirus-specific T-cell response in solid organ transplant recipients **Piera D'Angelo (Italy)**
- O045.** Differentiation-induced reduction in functional diversity restricts the ability of cytomegalovirus-specific CD8 T cells to eliminate virus-infected cells **Berislav Bošnjak (Germany)**
- O046.** Inhibition of Inflammasome Signaling by Human Cytomegalovirus UL84 **Wolfram Brune (Germany)**

15.45 - 17.15

SESSION 15: CMV in preterm infants

Chairs: **Soren Gantt (Canada)**, **Lia Syridou (Greece)**

Keynote Lectures

- Postnatal CMV infection in preterm infants: neonatal and long-term consequences **Rangmar Goelz (Germany)**
- Challenges in diagnosis and management of cCMV and pCMV in premies **Helen Payne (UK)**

16.35 - 17.15

Oral Presentations (O047 - O049 & LB006)

- O047.** Systematic Screening for Postnatal Cytomegalovirus Infection in Preterm Infants: Preliminary Results from an Ongoing Multicenter Prospective Study in Greece **Maria Eleni Papakonstantinou (Greece)**
- O048.** The Screen cCMV study: congenital CMV prevalence and infant hearing loss in an Australian population **Lisa Hui (Australia)**
- O049.** Addressing the gaps in CMV prevention in pregnancy: the burden of maternal cytomegalovirus infection across England **Christine E. Jones (UK)**
- LB(O)006.** Viral shedding in CMV-seropositive pregnant women receiving hygiene-based behavioral education in a highly seropositive population **Marisa Mussi-Pinhata (Brazil)**

17.15 - 17.30

Closing - Hand over

19.30

Farewell Dinner

POSTER PRESENTATIONS

13.45 - 14.30

Poster Presentations Session 1

- P001.** cCMV infection in an extremely preterm infant **Tina Uršič** (*Slovenia*)
- P002.** Modeling human cytomegalovirus (HCMV) infection and protective immunity at the nasal mucosal entry site **Einav Shasha** (*Israel*)*
- P003.** Epidemiology, impact of early treatment and predictors of adverse outcomes in congenital CMV infection: a Swiss nationwide prospective study **Renato Gualtieri** (*Switzerland*)
- P004.** Clinical Distribution of CMV DNA PCR Test Requests and Positivity Rates in Adult and Pediatric Patients: A Retrospective Evaluation **Kubra Evren** (*Turkey*)
- P005.** Sex differences in congenital CMV infection - an international cCMVnet study
Horst Buxmann (*Germany*)
- P006.** Valganciclovir dosing in preterm infants for the treatment of cytomegalovirus using population pharmacokinetic modelling **Xuanlin Liu** (*The Netherlands*)
- P007.** Evaluation of pUL56-derived peptides targeting the human cytomegalovirus terminase complex **Sarah Mafi** (*France*)
- P008.** Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database (CHARMD) and quality control of its integrated genotyping tool **Sophie Alain** (*France*)
- P009.** Comparison of Sanger Sequencing and the DeepChek® CMV Genotyping NGS Assay for Cytomegalovirus Antiviral Resistance Genotyping **Sarah Mafi** (*France*)
- P010.** Comparative analysis of the human cytomegalovirus helicase-primase complex for the development of a new therapeutic strategy **Camille Lefevre** (*France*)
- P011.** The long-running motivation to discover nuclear egress-directed antiherpesviral prototype drugs – helter skelter stepping forward **Manfred Marschall** (*Germany*)
- P012.** Use of AltoStar® CMV PCR Kit 1.5 in non-blood samples based on validation data and external quality assessment data **Abel Nessali** (*Germany*)
- P013.** The conundrum in CMV viraemia: To treat or not to treat? **Arjun Bhugra** (*UK*)
- P014.** Emergence of CMV drug-resistance (drug-R) in immunocompromised (IC) patients presenting multiple DNA virus infections **Graciela Andrei** (*Belgium*)
- P015.** Evaluation of CMV IgM Confirmation and IgG Avidity Testing Following High-Volume Automated Screening in a Tertiary Care Hospital **Peri Sohrabi-Mollayousefi** (*Turkey*)*
- P016.** An unusual case of disseminated CMV infection leading to encephalitis driven secondary HLH **Abhinav Kumar** (*UK*)
- P017.** Evaluating CMV vaccines targeting glycoprotein B and viral Fcγ receptors to prevent congenital CMV transmission in rhesus macaques **Husam Taher** (*USA*)
- P018.** Non-Canonical HCMV Immediate-Early Expression Patterns in Human Tumors: Biological Insights from a Novel Clinical Cytomegalovirus Isolate **Anna Caproni** (*Sweden*)

- P019.** The mCMV antigenic protein m164/gp36.5 is encoded on a polycistronic RNA during the immediate early phase **Anna Rebecca Siemes** (*Germany*)
- P020.** HCMV Reprograms Host Cell Metabolism to Support Viral Replication **Mohammad Pirouzfar** (*Finland*)
- P021.** Analytical evaluation of pooled urine CMV PCR for neonatal testing **Nikolaos Siafakas** (*Greece*)
- P022.** HCMV driven signaling rewires the mitochondrial metabolism via inhibition of complex II through SPI-PTPMT1 regulation **Sana Abdul Khaliq** (*Sweden*)
- P023.** Retrospective Evaluation of Cytomegalovirus DNA Positivity in Non-Blood Clinical Specimens **Kubra Evren** (*Turkey*)
- P024.** A 10-year diagnostic evaluation in Germany: cytomegalovirus as a major human herpesviral pathogen **Lucio Fortelny** (*Germany*)
- P025.** Latent MCMV infection activates epithelial-mesenchymal transition (EMT) of retinal pigment epithelium (RPE) cells following mitochondrial oxidative stress **Ming Zhang** (*USA*)
- P026.** Development of an iPSC-based model for latent HCMV infection **Oliver Maier** (*Germany*)
- P027.** Conditional-replication models of human cytomegalovirus latency in permissive cell types **Michael McVoy** (*USA*)
- P028.** Viral modulation of NK cell recognition: MATp1 controls m157-Ly49H interactions **Magdalena Medved** (*Croatia*)
- P029.** Disruption of the m152 Promoter IRFE sequence paradoxically enhances expression of m152 and IE1 during acute mCMV Infection **Marta Agacinska-Odroneic** (*Germany*)
- P030.** HCMV UL98 encodes a unique alkaline nuclease engaging host DNA repair pathways **Andrea Salvatore Albanese** (*Germany*)
- P031.** Transcriptomic signatures of innate immune dysregulation and myeloid activation are associated with hearing loss and neurological injury in congenital cytomegalovirus **Helen Payne** (*UK*)
- P032.** Human Cytomegalovirus Reprograms Breast Cancer Cells Toward a Triple-Negative and Metastatic Phenotype **Shaghayegh Hasanpour** (*Finland*)
- P033.** Opposing Effects of HCMV and Viperin-Derived ddhCTP on Host Protein Synthesis **Mohammadhassan Ansarizadeh** (*Finland*)
- P034.** IFN- γ compromises glutamatergic synapse development and impairs motor coordination following congenital CMV infection **Ilija Brizić** (*Croatia*)
- P035.** Multi-strain cytomegalovirus infections and viral evolution in children attending daycare **Irene Goerzer** (*Austria*)
- P036.** PYCR1 Links HCMV-Induced Metabolic Rewiring to Mitochondrial Respiration and ETC Remodelling **Iqra Anam Khawaja** (*Finland*)

- P037.** Investigation on the interactome of human cytomegalovirus RL11 proteins reveals that pUL6 induces angiogenesis through MERTK **Abel Viejo-Borbolla** (*Germany*)
- P038.** Baseline antibody levels predict the risk of BK polyomavirus associated nephropathy in kidney transplant recipients **Charlotte Vanhomwegen** (*Belgium*)
- P039.** Evaluation of the VIDAS®-IGRA-CMV assay for monitoring CMV-specific cellular immunity in seropositive kidney transplant recipients **Sébastien Hantz** (*France*)
- LB(P)001.** Targeting the HCMV glycoprotein pUL11 restores T cell control of infection **Penelope Kay-Fedorov** (*Germany*)
- LB(P)002.** Functional Inhibition of the Human Cytomegalovirus Immuno-evasin pUL11 **Leonard Alfred Skremm** (*Germany*)
- LB(P)003.** Evaluation of Cytomegalovirus IgG, IgM, IgG Avidity, and PCR Findings by Gender and Pregnancy Status at a Tertiary Care Center in Istanbul Over a 2.5-Year Period **Aysel Karatas** (*Turkey*)
- LB(P)004.** Modulation of cellular microRNA-219a-5p expression during Human Cytomegalovirus (HCMV) infection in the U373MG cell line **Arsinoe Chrysovalanti Thomaidou** (*Greece*)
- LB(P)005.** High-throughput Epitope Screening of Human Cytomegalovirus Immediate Early Protein 2 Reveals an Immunodominant CD4⁺ T-cell Hotspot **Eleni Panagiotti** (*USA*)
- LB(P)006.** One program, different clocks: cell type sets the pace and endpoint of HCMV infection **Noam Stern-Ginossar** (*Israel*)
- *P053.** Dual-purpose Dried Blood Spot Workflows: Combining CMV Detection and Proteomics in Support of Future Risk Stratification **Kia Hee Schultz Dungu** (*Denmark*)

* Poster presentation day has been adjusted due to travel constraints

13.00 - 14.00

Poster Presentations Session 2

- P040.** The emotional trajectory following maternal cytomegalovirus infection in pregnancy: a longitudinal cohort study from the CMV-preg registry **Pauline Sartori** (*Switzerland*)
- P041.** Priority topics in the diagnosis and management of Cytomegalovirus in pregnancy: a targeted guideline from the Belgian Healthcare Knowledge Centre (KCE) **Elena Costa** (*Belgium*)
- P042.** Improving the serological staging of CMV infection in pregnant women using an epitope-specific IgM microarray **David Niklas Springer** (*Austria*)
- P043.** Retrospective Diagnosis of CMV-Related Hearing Loss: The Experience of Two Portuguese Centers **Paulo Paixão** (*Portugal*)
- P044.** Withdrawn
- P045.** Neurodevelopmental Outcomes in Congenital Cytomegalovirus Infection: A Bayesian Model-Averaged Meta-Analysis **Serena Salomè** (*Italy*)
- P046.** The Australian Congenital CMV Register (ACMVR): measuring developmental outcomes and antiviral therapy use to drive clinical change **Hayley Smithers-Sheedy** (*Australia*)
- P047.** Neonatal CMV viral load in blood and urine is associated with disease severity at birth and long-term outcome in congenital CMV infection: An international cCMVnet study **Serena Salomè** (*Italy*)
- P048.** One-year neurodevelopmental outcomes among children with congenital CMV in New York State, US **Andrew Handel** (*USA*)
- P049.** Withdrawn
- P050.** Cytomegalovirus-based viral vectors elicit robust systemic and tissue-resident immune response against SARS-CoV-2 antigens **Maja Cokaric Brdovcak** (*Croatia*)
- P051.** Longitudinal analysis of HCMV-specific T-cell function reveals stable immune profiles but divergent antiviral control in older adults **Veronika Romashova** (*UK*)
- P052.** Maternal and household predictors of congenital cytomegalovirus (cCMV) in a diverse population undergoing universal neonatal screening **Stav David Mehaber** (*Israel*)*
- P053.** Presentation day adjusted due to travel constraints
- P054.** CMV-Associated Cytokine Remodeling and IL-17 Signaling in Glioblastoma **Maedeh Alipour** (*Finland*)
- P055.** The Role of Uterine NK cells in the Control of HCMV **Eleanor Bradley** (*UK*)
- P056.** Double Jeopardy: Congenital CMV and Holder Pasteurisation Deplete Breast Milk IgA, with Clinical Consequences for Neonates who are Preterm **Helen Payne** (*UK*)
- P057.** Strain-specific immunity and cytomegalovirus reinfection in seropositive pregnant women **Shannon Ross** (*USA*)

- P058.** Risk Factors for Maternal Cytomegalovirus Infection and Shedding: Implications for Prevention in Pregnancy **Karen Fowler (USA)**
- P059.** Re-evaluation of HHV-6 and EBV Shedding Alongside Cytomegalovirus (CMV) Reactivation in Breast Milk of Healthy CMV-Seropositive Women **Charikleia Gkioule (Germany)**
- P060.** Primary CMV infection in pregnancy: is there an additional diagnostic or predictive value of immunoblot analysis focusing on gB1 antibodies? **Alfred Lennart Bissinger (Germany)**
- P061.** Longitudinal Evolution of Brain MRI Abnormalities in Children with Congenital Cytomegalovirus Infection **Melpomeni Giorgi (Greece)**
- P062.** Limit of detection determination of CMV in umbilical cord blood (UCB) **Abel Nessali (Germany)**
- P063.** Is Routine Cerebrospinal Fluid Examination Still Relevant in Congenital Cytomegalovirus Infection? **Lidia Stopyra (Poland)**
- P064.** Presentation format updated to Oral Presentation
- P065.** Hemophagocytic Lymphohistiocytosis as a Fatal Complication of Congenital Cytomegalovirus Infection: Two Cases from a Single Tertiary Center
Katarzyna Mazur-Melewska (Poland)
- P066.** Postnatal CMV infection in extremely preterm infants: a single-center cohort study
Vykinta Brasiene (Lithuania)
- P067.** Current practices in antenatal CMV testing and management in Belgium **Elena Costa (Belgium)**
- P068.** A multiplexed loop-mediated isothermal amplification assay for the detection of congenital cytomegalovirus infection in newborns **Taylor Stanley (USA)**
- P069.** Universal Cytomegalovirus Antenatal Screening in General Practice – what do Australian general practitioners think?: A Cross-Sectional Survey **Lisa Hui (Australia)**
- P070.** Implementation of targeted first-trimester cytomegalovirus screening following antenatal risk-reduction counselling in Australia: a pilot study of feasibility, acceptability and psychological impact **Lisa Hui (Australia)**
- P071.** Impact of antenatal cytomegalovirus screening on knowledge and attitudes of postpartum women about congenital cytomegalovirus infection: A nationwide cross-sectional study in Greece **Sofia Benou (Greece)**
- P072.** Withdrawn
- P073.** Added value of EUROLINE Anti-CMV IgG immunoblot alongside avidity testing for the timing of maternal CMV infection during pregnancy **Astrid Desimpelaere (Belgium)**
- P074.** Maternal perception of CMV screening during pregnancy: a cross-sectional study of women undergoing enhanced CMV screening **Elodie Ribot (France)**
- P075.** First national data from systematic CMV screening during first trimester of pregnancy in France **Elodie Ribot (France)**

P076. Universal versus selective neonatal screening for congenital cytomegalovirus infection: impact on detection of clinically unrecognized disease **Gregor Nosan** (*Slovenia*)

P077. Feasibility and Outcomes of Universal and Targeted Neonatal Screening for Congenital Cytomegalovirus Infection **Melissa Fontalvo Acosta** (*Spain*)

P078. Assessment of Adherence to the Diagnostic Algorithm for Primary Cytomegalovirus (CMV) Infection During Pregnancy **Emmanouil Karofylakis** (*Greece*)

P079. Withdrawn

P080. Awareness and practices of perinatal care professionals about congenital cytomegalovirus infection: A nationwide cross-sectional study in Greece **Sofia Benou** (*Greece*)

P081. Promoting Behavioral Strategies for Cytomegalovirus (CMV) Risk Reduction Among Pregnant Women **Karen Fowler** (*USA*)

P082. The right to know about CMV: perspectives of pregnant women and families with lived experience of CMV **Hayley Smithers-Sheedy** (*Australia*)

P083. Improving maternal awareness of Cytomegalovirus infection: a controlled educational intervention study **Serena Salomè** (*Italy*)

P084. Fetal antiviral treatment decreases the risk of severe neurodevelopmental impairment among children with congenital CMV infection **Sofia Karagiannidou** (*Greece*)

P085. Awareness and knowledge of congenital cytomegalovirus infection (cCMV) among healthcare professionals and pregnant women: systematic review and meta-analysis **Anna Damatopoulou** (*Greece*)

P086. Automation in Dried Blood Spot testing **Karin Rottengatter** (*Germany*)

P087. Can digital PCR in amniotic fluid improve the prenatal diagnosis of congenital cytomegalovirus infection? **Liliana Gabrielli** (*Italy*)

LB(P)007. Fortification of breast milk with anti-CMV antibodies to prevent postnatal cytomegalovirus acquisition in preterm infants **Megan Connors** (*USA*)

LB(P)008. Limited-Sampling AUC-Guided Therapeutic Drug Monitoring Reveals High Variability in Ganciclovir Exposure in Infants Treated for Cytomegalovirus Infection **Justyna Czech-Kowalska** (*Poland*)

LB(P)009. Withdrawn

LB(P)010. Prenatal Valganciclovir Therapy in Congenital Cytomegalovirus Infection: Pregnancy Outcomes and Neonatal Results – A Single-Centre Retrospective Analysis **Waleed Alshamandi** (*Germany*)

LB(P)011. In utero battlefield: Modeling congenital CMV in trophoblast organoids **Anastazija Drongovskij** (*Netherlands*)

* Poster presentation day has been adjusted due to travel constraints

FACULTY INDEX



FACULTY INDEX

Ana Alarcón

Dr., Head of Neonatal Services, BCNatal (Hospital Sant Joan de Déu & Hospital Clínic), Institut de Recerca Sant Joan de Déu, Associate Professor of Paediatrics, Universitat de Barcelona Barcelona, Spain

Anders Åsberg

Professor, Department of Nephrology, Department of Transplantation Medicine, Division of Surgery and Specialized Medicine, Oslo University Hospital - Rikshospitalet, Norway

Daniel Blazquez Gamero

Pediatric Infectious Diseases Unit, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (i+12), Universidad Complutense CIBERINFEC, Madrid, Spain

Suresh Boppana

MD, Professor of Pediatrics & Microbiology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

Judith Breuer

MD, FRCPATH, FMedSci, Professor of Virology, Institute Child Health, University College London, United Kingdom

Wolfram Brune

MD, Professor of Virology, Head of Research Department, Virus-Host Interaction, Leibniz Institute of Virology (LIV), Hamburg, Germany

Christos Chatzakis

MD, MSc, PhD, Assistant Professor of Obstetrics and Gynecology N.K.U.A., Greece, Visiting Senior Lecturer King's College London

Caroline De Coninck

MD, Obstetrician and Fetal Medicine Specialist, PhD Candidate, Université Libre de Bruxelles (ULB), Department of Obstetrics and Gynecology, Hôpital Erasme, Bruxelles University Hospital, Brussels, Belgium, Board Member, European Congenital Cytomegalovirus Initiative (ECCI)

Gail J Demmler-Harrison

MD, Professor, Department of Pediatrics, Division Infectious Diseases, Baylor College of Medicine, Attending Physician, Pediatric Infectious Diseases Service, Lead, Congenital CMV and Congenital Infections Clinic, Texas Children's Hospital, Houston, Texas, USA

Dirk Dittmer

MPh.D., William R. Kenan, Jr. Distinguished Professor, Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, USA

Mario Fernandez-Ruiz

MD, PhD, Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Research Institute Hospital 12 de Octubre (i+12), Madrid, Spain

Ina Foulon

Professor, Department of Otorhinolaryngology and Head & Neck Surgery, Vrije Universiteit Brussels, University Hospital UZ Brussel, Brussels Health Campus. De Poolster, Rehabilitation Centre, Brussels, Belgium

Karen Fowler

DrPH, Professor, Pediatric Infectious Diseases, Department of Pediatrics, Heersink School of Medicine, University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA

Soren Gantt

MD PHD MPH, Professor and Chair, Department of Microbiology and Immunology, University of Montreal, Canada

Laura Gibson

M.D., Professor, Infectious Diseases and Immunology, Departments of Pediatrics and of Medicine, UMass Chan Medical School, Worcester, Massachusetts USA

Despoina Gkentzi

Associate Professor in Paediatric Infectious Diseases, School of Medicine, University of Patras, Greece



FACULTY INDEX

Rangmar Goelz

MD, Member of the Research Staff, Department of Neonatology and Center for Rare Congenital Infection, Tuebingen University Hospital, Tuebingen, Germany

Clive Gray

Professor of Immunology, Division of Immunology, Biomedical Research Institute, Stellenbosch University, Cape Town, South Africa

Meaghan Hancock

Assistant Professor, Department of Molecular and Cellular Biology, University of Guelph, Canada

Ilkka Helanterä

MD, PhD, Adj. Prof, Helsinki University Hospital, Transplantation and Liver Surgery, Helsinki, Finland

Atul Humar

Professor, Ajmera Transplant Center, University of Toronto, Canada

Chrissie Jones

Professor of Paediatric Immunity and Infection, University of Southampton, United Kingdom

Stipan Jonjić

Professor, MD, PhD, Center for Proteomics, University of Rijeka, Faculty of Medicine, Rijeka, Croatia

Vanda Juranic Lisnic

University of Rijeka, Faculty of Medicine, Center for Proteomics, Croatia

Jeremy Kamil

Associate Professor, Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, USA

Hannah Kaminski

Nephrology, Transplantation and Dialysis at Bordeaux University Hospital, France

Rajiv Khanna

AO FAHMS, Co-Director, Queensland Immunology Research Centre, Distinguished Scientist, Tumour Immunology Laboratory, QIMR Berghofer Medical Research Institute, Queensland, Australia

Tiziana Lazzarotto

Full Professor of Microbiology and Clinical Microbiology, Department of Medical and Surgical Sciences - DIMEC at Alma Mater Studiorum - University of Bologna, Head of the Operative Unit of Clinical Microbiology at IRCCS St. Orsola University Polyclinic, Bologna, Member of the Doctoral School Board "SURGICAL SCIENCES AND INNOVATIVE TECHNOLOGIES" Alma Mater Studiorum - University of Bologna, Italy

Marianne Leruez-Ville

MD, PhD, Head of Microbiology Laboratory at Necker - Hospital for Sick Children, Paris, France

Daniele Lilleri

MD, Microbiology and Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Per Ljungman

MD, PhD, FIDSA, FESCMID, Professor Emeritus, Department of Medicine Huddinge, Karolinska Institutet, Dept. of Infectious Diseases and Dept. of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Karolinska Comprehensive Cancer Center, Stockholm, Sweden

Hermione Lyall

Retired Consultant, Paediatric Infectious Diseases, Imperial College Healthcare Trust, and visiting professor, Imperial College, London, United Kingdom

Arnaud Marchant

Professor, European Plotkin Institute for Vaccinology, Université Libre de Bruxelles, Brussels, Belgium



FACULTY INDEX

Manfred Marschall

Professor of Virology (Prof.apl. Dr.med.habil. Dr. rer.nat.), Associate Professor, Principal Investigator (PI) and independent group leader of virological research, coordinator of Academia - Industry consortia, Harald zur Hausen Institute of Virology, Friedrich-Alexander, Universität Erlangen, Nürnberg (FAU), Germany

Michael McVoy

Professor of Pediatrics, Department of Pediatrics, Virginia Commonwealth University, Richmond Virginia, USA

Athanasios Michos

Professor of Pediatrics and Infectious Diseases, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Edward Mocarski

Emeritus Professor, Stanford and Emory Universities, USA

Eleni Nastouli

Dr., Professor of Virology, University College London, Consultant Virologist, UCLH, United Kingdom

Elizaveta Padalko

MD, PhD, Medical Microbiologist, Directory of AIDS Reference Laboratory, Associate Professor, Ghent University and Hospital, Ghent, Belgium

Vana Papaevangelou

Professor in Paediatric Infectious Diseases, National and Kapodistrian University of Athens, Athens, Greece

Genovefa Papanicolaou

MD, PhD, FIDSA, FASTCT, Director, Infectious Disease and Allergy Service, Attending Physician, Department of Subspecialty Medicine, Memorial Sloan Kettering Cancer Center, Professor, Weill Cornell Medicine, Cornell University, New York, USA

Helen Payne

Senior Clinical Lecturer in Paediatric Infectious Diseases and Immunology, Imperial College London, United Kingdom

Emma Poole

Division of Virology, Department of Pathology, University of Cambridge, United Kingdom

John G. Purdy

Associate Professor, Immunobiology, University of Arizona, USA

William Rawlinson

Senior Medical Virologist NSWHP, Professor University of NSW, Australia

Matthew Reeves

Professor of Viral Pathogenesis, Institute of Infection, Immunity & Transplantation, UCL, United Kingdom

Shannon Ross

Professor of Pediatrics and Microbiology, Pediatric Infectious Diseases, University of Alabama at Birmingham, USA

Mark Schleiss

Professor and Attending Physician, Masonic Children's Hospital and University of Minnesota Physicians, University of Minnesota Medical School, Department of Pediatrics, Division of Pediatric Infectious Diseases and Institute for Molecular Virology, USA

John Sinclair

Emeritus Professor, Cambridge Institute for Therapeutic Immunology and Infectious Disease, Department of Medicine, University of Cambridge, United Kingdom

George Sourvinos

Professor of Clinical Virology, Medical School, University of Crete, Heraklion, Greece



FACULTY INDEX

Thomas Stamminger

Prof. Dr., Director, Institute of Virology, Ulm University Medical Center, Ulm, Germany

Maria Stamouli

Consultant Hematologist, Stem Cell Transplant Unit, 2nd Department of Internal Medicine Propaedeutic, Attikon University Hospital, Athens, Greece

Richard Stanton

Professor of Virology, Cardiff University, United Kingdom

Noam Stern-Ginossar

PhD, Professor, Department of Molecular Genetics, Weizmann Institute of Science, Israel

Nikolaos V. Sipsas

MD, FIDSA, Professor, Medical School, National and Kapodistrian University of Athens, Attending Physician, Infectious Diseases Unit and Department of Internal Medicine, Head, Infection Control Committee, General Hospital of Athens Laikon, Athens, Greece, President, Hellenic Society for Infectious Diseases

Lia Syridou

MD, PhD, Consultant in Pediatrics and Pediatric Infectious Diseases, University General Hospital Attikon, Athens, Greece, Secretary of the Hellenic Society for Pediatric Infectious Diseases

Natacha Teissier

Pediatric ENT department, Robert Debré Hospital, NeuroDiderot, Paris City University, France

Sotirios Tsiodras

MD, MSc, PhD, FIDSA, FESCMID, Professor of Medicine and Infectious Diseases, National & Kapodistrian University of Athens Medical School, Chair, 4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece, Chair, National Committee of Public Health experts

Pamela Vallely

Professor of Medical Virology, Microbiology and Virology Unit, University of Manchester, Manchester, United Kingdom

Spyridoula Vasileiou

Assistant Professor, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist, USA

Yves Ville

Professor and Chairman of the Department of Obstetrics and Fetal Medicine at Necker - Enfants - Malades Hospital at the Paris Descartes University, France

Ann Vossen

Leiden University Medical Center, Leiden Center for Infectious Diseases, Dept Medical Microbiology & Infection Control, the Netherlands

Michael Weekes

BEM, PhD, FRCP, Deputy Director, Cambridge Institute for Medical Research, Professor of Viral Immunology, Honorary Consultant, Infectious Diseases, Cambridge, United Kingdom

Mark Wills

Cambridge Institute for Therapeutic Immunology and Infectious Disease, Department of Medicine, University of Cambridge, United Kingdom

Dana Wolf

Hadassah Medical Center, The Hebrew University Faculty of Medicine, Jerusalem, Israel

Andrew Yurochko

Professor Vice Chair, Dept. of Microbiology & Immunology, Carroll Feist Endowed Chair in Viral Oncology, Director and PI, CoBRE Center of Applied Immunology and Pathological Processes, Director, Center of Excellence for Emerging Viral Threats, Louisiana State University Health - Shreveport, Shreveport, USA

19th International
CMV Workshop
& **ECCI 2026**
Megaron Athens International
Conference Centre

1-4
november
Athens
Greece

WORKSHOP INFORMATION



Registrations

Pre-registration counter

For participants who have already registered. Please have the confirmation e-mail sent by the Meeting Secretariat close at hand. If you still have an outstanding payment you may settle your account by debit or credit card (Visa & Mastercard will be accepted). EURO (€) only.

Onsite registration counter

For participants registering and paying their registration fees onsite: you will need to fill in an online registration form. Payment will be accepted by debit or credit card (Visa & Mastercard will be accepted). EURO (€) only.

Onsite registration fees

Category	Regular 01/08/2026 - onsite
ECCI & ESPID Members	660 €
Non-members	750 €
Students / Trainees / Nurses / Fellows	510 €
Industry*	600 €
Day pass	180 €
Virtual Attendance	350 €

NOTES:

- Students must be PhD candidates at the time of registration and verify by providing a written poof of their valid student ID card or an official certificate from their Academic Institution.
- Trainees, Nurses, Fellows should verify by providing an official certificate from their Institution.



Registrations

Attendees Registration Fees include:

- Delegate's badge
- Admission to the scientific sessions
- Admission to the exhibition hall
- Congress scientific material
- Certificate of attendance
- Accreditation
- Coffee breaks and light lunches during the meeting
- Welcome Reception on the first evening
- One-year unlimited on-demand access to the recorded scientific sessions (subject to speakers' consent)

Industry Registration Fees include:

- Exhibitor's badge
- Admission to the scientific sessions
- Admission to the exhibition hall
- Coffee breaks and light lunches during the meeting
- Welcome Reception on the first evening
- One-year unlimited on-demand access to the recorded scientific sessions (subject to speakers' consent)

Virtual Attendance Registration Fees include:

- Live virtual access during the Workshop
- One-year unlimited on-demand access to the recorded scientific sessions (subject to speakers' consent).
- Certificate of attendance
- Accreditation (applies only to participation in the live scientific programme)

Name Badges

Participants will receive their badges onsite at the registration desk. The meeting badge should be worn by all participants at all times during the meeting to ensure access to the relevant areas. This includes the scientific sessions, the coffee-breaks and lunches, the exhibition area and other areas of the meeting venue as well as the social activities. Only participants wearing their meeting badge will be admitted to the above mentioned areas and activities.

The following badge colors are in use at the Workshop:

Faculty	Delegate	Other
---------	----------	-------



Presentation Guidelines

General

English is the official language of the Workshop, therefore all types of presentations must be prepared and delivered in English. The time reserved for each presentation varies according to the presentation and session type.

Oral Presentations

Oral presentations are organized in sessions according to the topic of each abstract. Authors are asked to follow the assigned time strictly, the remaining time for the presentation and discussion will be announced and controlled by the session chair.

All abstracts are available in the abstract book, which is uploaded on the Workshop website

Supported Presentation formats

Please prepare your presentation preferably using PowerPoint 2017 or newer versions, however older versions are also supported.

Supported file types

Presentation: PPT, PPA, PPTA, PPTX, PDF

Video: AVI, MPG, MKV, MOV, MP4, WMV

Audio: WMA, MP3, WAV

Please note that the presentations are best to be prepared in 16:9 ratio, however 4:3 is also supported.

For MAC devices: Please bring your own adaptor & charger.

Presentation preview desk

You will be assisted in the Presentation preview desk by the technicians, who will help you upload your presentation to the intranet. You will also be able to review your presentation and to verify that it has been transferred correctly to the network.

Your presentation must be uploaded as much in advance as possible, but no later than TWO HOURS BEFORE the beginning of the respective session. Presentations for an early morning session must be uploaded the day before. When uploading multimedia files, do not forget to double check all your video files and all links to these multimedia that files are functional.

In the Auditorium

Your presentation will be transferred directly to the Auditorium through the intranet.

Once the presentation is launched on the computer in the Auditorium, you will advance your own slideshow using the remote control.

All speakers are requested to be present in the lecture room 10 MINUTES BEFORE the session starts to meet with the session chair. Please, do not come at the last minute with your own computer into the lecture room: you will NOT BE ABLE to connect it. All presentations must be uploaded in the Presentation Preview desk beforehand.

In case any problems arise, there will be assistance staff in the Auditorium.



Certificates

Certificates of Attendance

All registered delegates will be able to download their Certificate of Attendance after the end of the Workshop. Instructions will be sent in due course.

Accreditation

The 19th International CMV Workshop & ECCI 2026, ATHENS, Greece 01/11/2026 - 04/11/2026, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **24.0 European CME credits (ECMEC®s)**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at <https://edhub.ama-assn.org/pages/applications>.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Information regarding the conversion of EACCME® credits

Credit will be converted based on one (1) hour of participation equalling one credit for all activities. Physicians wishing to convert EACCME® credits to AMA PRA Category 1 Credit™ will be required to access the AMA website at <https://edhub.ama-assn.org/pages/applications> to obtain the necessary paperwork and instructions. Physicians and other health care professionals will be required to pay a processing fee to the AMA.

For other countries, please contact the relevant national/regional accreditation authority.

EACCME® Credits

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 22 of UEMS 2023.07.

The EACCME® awards ECMEC®s on the basis of 0,5 ECMEC® for 30 minutes of CME with a maximum of 8 ECMEC®s per day. cf. Chapter XIII of UEMS 2023.07.

Certificates of Accreditation

During the Workshop, participants will be able to evaluate the sessions they have attended in real time via the AttendPro mobile app. Certificates of Accreditation will be sent out by e-mail a few days after the completion of the Workshop.



Poster Presentation Instructions

Posters Dimensions

- Portrait orientation
- **A0 Poster size** - 84,1 cm (width) x 118,9 cm (height)
- Posters printed on a single sheet are strongly recommended.

Important Information

- Posters are **numbered** and must be mounted on the corresponding poster board.
- Each poster board will display the **poster number** and the **poster session**.
- Mounting materials will be provided on site.
- Posters must be mounted on **Sunday 1 November, between 09:00 and 12:00 (noon)**.
- Posters may be removed on **Wednesday 4 November**, after the last coffee break, **from 16:00 onwards**.
- Presenting authors are **required** to be present at their posters during their assigned poster presentation session (Monday 2 November, or Tuesday 3 November).
- Presenters are also welcome to be present in the poster area during the **coffee breaks and lunch breaks on Sunday 1 November and Wednesday 4 November**, to encourage informal discussions with delegates.
- The mounting, removal, and safekeeping of posters are the sole responsibility of the presenters.
- Posters remaining on the boards after the designated removal time will be removed and disposed of by the workshop staff. Unfortunately, they cannot be stored or returned.
- All abstracts are available in the abstract book, which is uploaded on the Workshop website

GENERAL INFORMATION

1-4
november
Athens
Greece

19th International
CMV Workshop
& ECCI 2026
Megaron Athens International
Conference Centre



General Information

Venue

The Megaron Athens International Conference Centre is one of the finest and most technologically advanced conference venues in Europe. Situated in the city centre yet surrounded by its own extensive landscaped gardens, Megaron offers a stunning environment, exceptional aesthetics, cutting edge technology and unrivalled client service.

How to get there

The Megaron Athens International Conference Centre is situated at the corner of Vas. Sofias Avenue and Kokkali St. This is a location most people know and you'll find it easy to get to. If you come by taxi, just tell the driver you want the Concert Hall. He won't need any further directions!

Visitors to Athens can easily find the Concert Hall:

- From the airport you can take bus X95, or a 35 minute ride on the Metro will bring you to the Concert Hall.
- From the railway station, it's just 30 minutes to the Concert Hall Metro station.
- From Piraeus it's just a few minutes ride on the Metro.

For more information, call +30-210-7282311.

MEGARON, THE ATHENS CONCERT HALL

Vas. Sofias Ave. & Kokkali St. 1,

115 21 Athens

Telephone: +30-210-7282000

Official Language

The official language of the Workshop is English.

Banking Facilities and ATMs

Banks in Athens are generally open from Monday to Friday, from 08:00 to 14:00.

If you require additional information, please ask at the registration desk staff. They will be able to direct you to the closest bank. There are cash machines (ATMs) nearby. For further information, please contact the registration desk.

Insurance, Liability

All participants are cautioned that the 19th International CMV Workshop & ECCI 2026 (Organizers, PCO and Meeting Venue) are not liable for any losses, accidents or damage to persons or private property. Participants and accompanying persons are strongly advised to make their own arrangements in respect to health, personal and travel insurance in their country of origin.

1-4
november
Athens
Greece

19th International
CMV Workshop
& ECCI 2026
Megaron Athens International
Conference Centre



General Information

In case of emergency

You can use the following numbers:

- Police 100
- Emergency Number 112
- First Aid 166
- Fire Department 199

Internet access / Wi-fi

Wireless internet is available in all areas at the conference venue during the conference time.

Mobile Phones

All participants are asked to switch mobile phones off or put them to “silent mode” during the scientific sessions.

Smoking

Smoking is not permitted in closed public areas, including the conference venue, airports, hotels, restaurants, shops, or workplaces and is only allowed in specific designated/signed areas.

Electricity

In Greece the electrical current is 220V, AC (50 Hz). Electrical sockets comply with European regulations.

Currency

Since 2002, the currency used in Greece is the euro (€). One euro is divided up into 100 cents.

Weather

While the beginning of November in Athens marks the arrival of autumn, the weather is generally mild and pleasant, with plenty of sunny days and comfortable temperatures.

The average temperature this month is around 18°C, while the average low is approximately 13°C and the average high reaches around 23°C. Early November is usually a pleasant time to explore the city, although cooler evenings and occasional rainfall can be expected.

1-4
november
2026
Athens
Greece

19th International CMV Workshop & ECCI 2026

Megaron Athens International
Conference Centre



Sponsors & Supporters

BRONZE



EXHIBITOR



SPONSORS



BioAnalytica
BIOTECHNOLOGY SYSTEMS



J. M. KYRIAKIDIS S.A.

COMMUNICATION PARTNER



pathogens
an Open Access Journal by MDPI

SUPPORTERS



European congenital
cytomegalovirus initiative



ΕΛΛΗΝΙΚΗ ΕΤΑΙΡΕΙΑ
ΠΑΙΔΙΑΤΡΙΚΩΝ ΛΟΙΜΩΣΕΩΝ



TOOLS FOR INVESTIGATING

congenital conditions

KITS FOR QUANTITATIVE DETECTION

- AltoStar® CMV PCR Kit 1.5
- AltoStar® HSV PCR Kit 1.5
- AltoStar® Parvovirus B19 PCR Kit 1.5
- AltoStar® TREC & KREC PCR Kit 1.5 (RUO)*

KITS FOR QUALITATIVE DETECTION

- AltoStar® Treponema pallidum PCR Kit 1.5 (RUO)*
- RealStar® Chagas PCR Kit 1.0
- RealStar® Zika Virus RT-PCR Kit 1.0



AltoStar® Dried Blood Spots Pretreatment Buffer 1.5 (RUO)*

Enhanced performance of DBS extraction with the AltoStar® Workflow

Meet us
at booth
#B1



VISIT OUR WEBSITE

for further information about the altona PCR range of products.

altona-diagnostics.com | powered by integrity



J. M. KYRIAKIDIS S.A.
MEDICAL TECHNOLOGIES

Vitros® Infectious Disease Testing


For Maximum Safety and Lab Efficiency.

More than 80 years commitment to addressing your needs in Blood Screening and Diagnostic Testing:

- Uncompromised Sensitivity and Specificity
- Integrity of Results
- Full Process Control
- Productivity Efficiency
- Best-in-Class Service & Support

High Performance ToRC panel

- CMV IgG & IgM
- Rubella IgG & IgM
- Toxoplasma IgG & IgM





From Sample to Insight.

Advancing Infectious Disease
Research and Diagnostics.

bioanalytica.gr

Your Biotech
Solutions Partner



BioAnalytica
BIOTECHNOLOGY SYSTEMS

**19th International
CMV Workshop
& ECCI 2026**
Megaron Athens International
Conference Centre

1-4
november
2026
Athens
Greece

Workshop Secretariat



12 Thessalonikis str., 15344 Gerakas,
Athens - Greece
+30 210 60 48 260
www.free-spirit.gr